CD3E (P07766) variants and mutations
CD3E (also known as P07766) is a human protein-coding gene encoding a t-cell surface glycoprotein CD3 epsilon chain protein. It helps assemble the T-cell receptor complex and transduces antigen-recognition signals through its cytoplasmic signaling motifs. Biallelic pathogenic variants can impair T-cell development and cause severe combined immunodeficiency. This analysis covers 370 CD3E variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes immunodeficiency 18, neoplasm, and plasma cell myeloma. Example CD3E variants include Q2Q, S3L, and S3G.
Variant analysis overview
- Gene: CD3E
- Protein: P07766
- UniProt accession: P07766
- Organism: Homo sapiens
- Variants analyzed: 370
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 238 unspecified-consequence records; 39 synonymous variants; 11 frameshift variants; 5 stop-gained variants; 70 missense variants; 2 splice-region variants; 1 in-frame insertions; 3 in-frame deletions; 2 substitution
- Prediction scores: 353 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 18, neoplasm, plasma cell myeloma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, type 1 diabetes mellitus, small cell lung carcinoma, Ascites, B-cell acute lymphoblastic leukemia, T-B- severe combined immunodeficiency, T-B+ severe combined immunodeficiency.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 2 domains; 2 post-translational modification sites.
- Structural context: 220 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CD3E variants
Examples include Q2Q, S3L, S3G, S3*, S3S, G4D, G4G, T5S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2Q (p.Gln2Gln), rs1565509562, gnomAD 11-118304958-G-A, CADD 2.52
- S3L (p.Ser3Leu), rs771841066, ClinGen CA6301538, cosmic curated COSV10527, ClinVar RCV001844519, REVEL 0.03, MetaLR 0.10, Uncertain significance, not specified; Immunodeficiency 18
- S3G (p.Ser3Gly), gnomAD 11-118304958-GTC-, CADD 18.00
- S3* (p.Ser3Ter), gnomAD 11-118304960-C-A, CADD 26.60
- S3S (p.Ser3Ser), rs776010793, gnomAD 11-118304961-G-A, CADD 3.46
- G4D (p.Gly4Asp), Ensembl rs377513318, MetaLR 0.32, MetaSVM -0.80
- G4G (p.Gly4Gly), rs997765159, gnomAD 11-118304964-C-A, CADD 1.48
- T5S (p.Thr5Ser), gnomAD 11-118304965-A-T, REVEL 0.01, MetaLR 0.10
- T5I (p.Thr5Ile), gnomAD 11-118304966-C-T, REVEL 0.08, MetaLR 0.16
- T5T (p.Thr5Thr), rs1162588226, gnomAD 11-118304967-T-C, CADD 0.49
- H6P (p.His6Pro), rs1009249314, ClinGen CA229495803, ClinVar RCV001043238, TOPMed rs1009249314, AlphaMissense 0.07, MetaLR 0.06, Uncertain significance, Immunodeficiency 18
- H6H (p.His6His), gnomAD 11-118304970-C-T, CADD 8.13
- R8R (p.Arg8Arg), gnomAD 11-118304974-A-C, CADD 7.76
- R8T (p.Arg8Thr), gnomAD 11-118304975-G-C, REVEL 0.04, MetaLR 0.13
- V9V (p.Val9Val), rs200915775, gnomAD 11-118304979-T-C, CADD 6.91
- L10P (p.Leu10Pro), gnomAD 11-118304981-T-C, REVEL 0.45, MetaLR 0.37
- L10L (p.Leu10Leu), rs201804714, gnomAD 11-118304982-G-A, CADD 9.77
- G11A (p.Gly11Ala), gnomAD 11-118304981-TG-T, CADD 24.70
- G11C (p.Gly11Cys), gnomAD 11-118304983-G-T, REVEL 0.19, MetaLR 0.22
- G11D (p.Gly11Asp), gnomAD 11-118304984-G-A, REVEL 0.32, MetaLR 0.37
- G11V (p.Gly11Val), gnomAD 11-118304984-G-T, REVEL 0.38, MetaLR 0.32
- G11G (p.Gly11Gly), gnomAD 11-118304985-C-G, CADD 6.97
- L12I (p.Leu12Ile), NCI-TCGA TCGA novel, MetaLR 0.31, MetaSVM -0.46, Variant assessed as somatic; moderate impact.
- C13R (p.Cys13Arg), gnomAD 11-118304989-T-C, REVEL 0.35, MetaLR 0.26
- C13Y (p.Cys13Tyr), gnomAD 11-118304990-G-A, REVEL 0.29, MetaLR 0.29
- C13C (p.Cys13Cys), gnomAD 11-118304991-C-T, CADD 13.10
- L14V (p.Leu14Val), gnomAD 11-118304992-C-G, REVEL 0.24, MetaLR 0.29
- L14L (p.Leu14Leu), rs765624002, gnomAD 11-118304994-C-T, CADD 9.01
- L15F (p.Leu15Phe), Ensembl rs1948097990, REVEL 0.22, MetaLR 0.28
- L15S (p.Leu15Ser), Ensembl rs1948097974, MetaLR 0.28, MetaSVM -0.73
- S16L (p.Ser16Leu), rs1472836910, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, TOPMed rs1472836910, REVEL 0.07, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- S16T (p.Ser16Thr), gnomAD rs1233910437, REVEL 0.11, MetaLR 0.15
- S16* (p.Ser16Ter), gnomAD 11-118304999-C-G, CADD 34.00
- V17A (p.Val17Ala), Ensembl rs1948112513
- G18S (p.Gly18Ser), NCI-TCGA TCGA novel, REVEL 0.31, MetaLR 0.36, Variant assessed as somatic; moderate impact.
- G18C (p.Gly18Cys), gnomAD 11-118307290-G-T, REVEL 0.20, MetaLR 0.28
- G18R (p.Gly18Arg), gnomAD 11-118307290-G-C, REVEL 0.31, MetaLR 0.35
- G18V (p.Gly18Val), gnomAD 11-118307291-G-T, REVEL 0.30, AlphaMissense 0.22
- G18G (p.Gly18Gly), rs1126924, gnomAD 11-118307292-C-T, CADD 9.68
- V19I (p.Val19Ile), rs143630318, ClinGen CA6301567, cosmic curated COSV62345, ClinVar RCV001696915, REVEL 0.02, MetaLR 0.05, Conflicting interpretations, not provided; Immunodeficiency 18
- V19F (p.Val19Phe), gnomAD 11-118307293-G-T, REVEL 0.07, MetaLR 0.08
- W20G (p.Trp20Gly), rs2496826882, ClinGen CA382779997, ClinVar RCV003042187, Uncertain significance, Immunodeficiency 18
- W20L (p.Trp20Leu), rs914391006, ClinGen CA229497380, cosmic curated COSV10068, ClinVar RCV001910167, REVEL 0.23, MetaLR 0.21, Uncertain significance, Immunodeficiency 18
- W20* (p.Trp20Ter), gnomAD 11-118307297-G-A, CADD 36.00
- G21R (p.Gly21Arg), rs774506155, ExAC rs774506155, gnomAD rs774506155, REVEL 0.31, MetaLR 0.31, Variant assessed as somatic; moderate impact.
- G21E (p.Gly21Glu), gnomAD 11-118307300-G-A, REVEL 0.30, MetaLR 0.30
- G21G (p.Gly21Gly), rs200268620, gnomAD 11-118307301-G-T, AlphaMissense 0.52, MetaLR 0.23
- Q22K (p.Gln22Lys), TOPMed rs1257306367, REVEL 0.09, MetaLR 0.14
- Q22R (p.Gln22Arg), gnomAD 11-118307303-A-G, REVEL 0.16, MetaLR 0.23
- D23Y (p.Asp23Tyr), NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, REVEL 0.18, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- D23D (p.Asp23Asp), gnomAD 11-118307307-T-C, AlphaMissense 0.16, MetaLR 0.49
- G24V (p.Gly24Val), rs2496828884, ClinGen CA382780762, ClinVar RCV002654072, Uncertain significance, Immunodeficiency 18
- G24S (p.Gly24Ser), gnomAD 11-118307308-G-A, REVEL 0.14, MetaLR 0.13
- G24D (p.Gly24Asp), gnomAD 11-118308427-G-A, REVEL 0.03, MetaLR 0.05
- G24G (p.Gly24Gly), gnomAD 11-118308428-T-C, CADD 0.19
- N25D (p.Asn25Asp), rs201867379, ClinGen CA6301587, ClinVar RCV000385303, ExAC rs201867379, REVEL 0.01, MetaLR 0.06, Uncertain significance, Immunodeficiency 18
- N25K (p.Asn25Lys), TOPMed rs1948119230, MetaLR 0.07, MetaSVM -1.04
- N25M (p.Asn25Met), gnomAD 11-118308428-TA-T, CADD 4.26
- N25S (p.Asn25Ser), gnomAD 11-118308430-A-G, REVEL 0.02, MetaLR 0.06
- N25N (p.Asn25Asn), gnomAD 11-118308431-T-C, CADD 1.66
- E26K (p.Glu26Lys), gnomAD rs1948119244, REVEL 0.13, MetaLR 0.18
- E26* (p.Glu26Ter), gnomAD 11-118308432-G-T, CADD 47.00
- E26G (p.Glu26Gly), gnomAD 11-118308433-A-G, REVEL 0.12, MetaLR 0.20
- E26E (p.Glu26Glu), gnomAD 11-118308434-A-G, CADD 7.66
- E26D (p.Glu26Asp), gnomAD 11-118308434-A-T, REVEL 0.01, MetaLR 0.09
- E27* (p.Glu27Ter), NCI-TCGA Cosmic COSV6234, Variant assessed as somatic; high impact.
- E27K (p.Glu27Lys), NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, MetaLR 0.09, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- E27E (p.Glu27Glu), gnomAD 11-118308437-A-G, CADD 0.25
- M28I (p.Met28Ile), Ensembl rs1948119276, REVEL 0.02, MetaLR 0.10
- M28L (p.Met28Leu), rs759815699, ClinGen CA6301588, ClinVar RCV001103936, ClinVar RCV005520440, REVEL 0.01, MetaLR 0.05, Uncertain significance, Immunodeficiency 18; Inborn genetic diseases
- M28V (p.Met28Val), gnomAD 11-118308438-A-G, REVEL 0.02, MetaLR 0.09
- M28T (p.Met28Thr), gnomAD 11-118308439-T-C, REVEL 0.01, MetaLR 0.05
- M28K (p.Met28Lys), gnomAD 11-118308439-T-A, REVEL 0.02, MetaLR 0.06
- G29D (p.Gly29Asp), TOPMed rs1446052314, gnomAD rs1446052314, REVEL 0.02, MetaLR 0.07
- G29V (p.Gly29Val), TOPMed rs1446052314, gnomAD rs1446052314, REVEL 0.08, MetaLR 0.14
- G29C (p.Gly29Cys), gnomAD 11-118308441-G-T, REVEL 0.10, MetaLR 0.26
- p.Gly29 Gly30insPhePhe, gnomAD 11-118312153-G-GT, CADD 1.24
- G30A (p.Gly30Ala), rs202079083, ClinGen CA382781514, ClinVar RCV002811271, AlphaMissense 0.06, MetaLR 0.04, Uncertain significance, Immunodeficiency 18
- G30D (p.Gly30Asp), TOPMed rs202079083
- G30S (p.Gly30Ser), rs773135734, ClinGen CA6301610, ClinVar RCV001930591, ClinVar RCV003365553, REVEL 0.06, MetaLR 0.04, Conflicting interpretations, Inborn genetic diseases; Immunodeficiency 18
- G30V (p.Gly30Val), TOPMed rs202079083, MetaLR 0.07, MetaSVM -1.05
- I31T (p.Ile31Thr), gnomAD 11-118312159-T-C, REVEL 0.06, MetaLR 0.06
- T32A (p.Thr32Ala), TOPMed rs1396522987, gnomAD rs1396522987, REVEL 0.02, MetaLR 0.06
- T32K (p.Thr32Lys), gnomAD 11-118312162-C-A, REVEL 0.02, MetaLR 0.06
- T32T (p.Thr32Thr), gnomAD 11-118312163-A-G, CADD 2.07
- Q33H (p.Gln33His), rs1948139036, ClinGen CA382781555, ClinVar RCV001345315, TOPMed rs1948139036, REVEL 0.06, MetaLR 0.09, Uncertain significance, Immunodeficiency 18
- Q33E (p.Gln33Glu), gnomAD 11-118312164-C-G, REVEL 0.09, MetaLR 0.05
- Q33* (p.Gln33Ter), gnomAD 11-118312164-C-T, CADD 35.00
- T34P (p.Thr34Pro), gnomAD rs1948139067, REVEL 0.04, MetaLR 0.06
- T34H (p.Thr34His), rs1948139048, gnomAD 11-118312165-AG-A, CADD 8.91
- T34I (p.Thr34Ile), gnomAD 11-118312168-C-T, REVEL 0.02, MetaLR 0.06
- P35Q (p.Pro35Gln), gnomAD rs1422573053, REVEL 0.11, MetaLR 0.08
- P35S (p.Pro35Ser), rs143949187, ClinGen CA6301611, ClinVar RCV000527609, ClinVar RCV003401294, REVEL 0.04, MetaLR 0.05, Benign/Likely benign, not specified; Immunodeficiency 18; not provided
- Y36* (p.Tyr36Ter), TOPMed rs1948141834
- Y36N (p.Tyr36Asn), gnomAD rs1397810052, REVEL 0.22, MetaLR 0.25
- K37I (p.Lys37Ile), gnomAD 11-118312624-A-T, REVEL 0.07, MetaLR 0.20
- S39C (p.Ser39Cys), NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, Variant assessed as somatic; moderate impact.
- S39Y (p.Ser39Tyr), rs369130631, ClinGen CA6301628, ClinVar RCV001963801, ClinVar RCV004044568, REVEL 0.24, MetaLR 0.23, Uncertain significance, Immunodeficiency 18; Inborn genetic diseases
- S39F (p.Ser39Phe), gnomAD 11-118312630-C-T, REVEL 0.32, MetaLR 0.23
- S39S (p.Ser39Ser), rs1369383330, gnomAD 11-118312631-C-T, CADD 13.10
- I40T (p.Ile40Thr), rs2134766495, ClinGen CA382781729, ClinVar RCV001913962, Ensembl rs2134766495, AlphaMissense 0.98, MetaLR 0.30, Uncertain significance, Immunodeficiency 18
- S41P (p.Ser41Pro), gnomAD 11-118312635-T-C, REVEL 0.42, MetaLR 0.28
- G42E (p.Gly42Glu), Ensembl rs2134766503
- G42R (p.Gly42Arg), cosmic curated COSV10747, ExAC rs762766043, gnomAD rs762766043, MetaLR 0.28, MetaSVM -0.63
- T43I (p.Thr43Ile), gnomAD rs1157071097, MetaLR 0.06, MetaSVM -1.07
- T43S (p.Thr43Ser), gnomAD rs1157071097, REVEL 0.13, MetaLR 0.11
- T44A (p.Thr44Ala), Ensembl rs1591269024, MetaLR 0.14, MetaSVM -1.00
- V45I (p.Val45Ile), ExAC rs771023412, gnomAD rs771023412, REVEL 0.22, MetaLR 0.25
- I46T (p.Ile46Thr), gnomAD rs200184895, REVEL 0.07, MetaLR 0.06
- I46Y (p.Ile46Tyr), gnomAD 11-118312648-TA-T, CADD 4.59
- I46M (p.Ile46Met), gnomAD 11-118312652-A-G, REVEL 0.07, MetaLR 0.09
- L47S (p.Leu47Ser), gnomAD 11-118312654-T-C, REVEL 0.43, MetaLR 0.39
- T48A (p.Thr48Ala), Ensembl rs1565511269, MetaLR 0.25, MetaSVM -0.85
- C49F (p.Cys49Phe), TOPMed rs1423326426, gnomAD rs1423326426, REVEL 0.62, MetaLR 0.45
- C49S (p.Cys49Ser), rs1948142016, ClinGen CA382781854, ClinVar RCV002718120, Ensembl rs1948142016, AlphaMissense 0.98, MetaLR 0.43, Uncertain significance, Inborn genetic diseases
- C49G (p.Cys49Gly), gnomAD 11-118312659-T-G, REVEL 0.67, MetaLR 0.43
- P50L (p.Pro50Leu), Ensembl rs1948142068, MetaLR 0.26, MetaSVM -0.56
- P50R (p.Pro50Arg), gnomAD 11-118312663-C-G, REVEL 0.31, MetaLR 0.23
- Q51H (p.Gln51His), ExAC rs774294885, gnomAD rs774294885, REVEL 0.10, MetaLR 0.05
- Q51K (p.Gln51Lys), Ensembl rs1948142082, MetaLR 0.05, MetaSVM -1.05
- Y52F (p.Tyr52Phe), TOPMed rs1373611207, gnomAD rs1373611207, REVEL 0.05, MetaLR 0.11
- P53H (p.Pro53His), gnomAD 11-118312672-C-A, REVEL 0.10, MetaLR 0.08
- P53P (p.Pro53Pro), rs759367644, gnomAD 11-118312673-T-G, CADD 5.85
- G54A (p.Gly54Ala), Ensembl rs200651235, REVEL 0.04, MetaLR 0.11
- G54E (p.Gly54Glu), NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, MetaLR 0.06, MetaSVM -1.07, Variant assessed as somatic; moderate impact.
- G54R (p.Gly54Arg), gnomAD 11-118312674-G-C, REVEL 0.05, MetaLR 0.16
- S55Y (p.Ser55Tyr), TOPMed rs1188442723, gnomAD rs1188442723, REVEL 0.10, MetaLR 0.05
- S55T (p.Ser55Thr), gnomAD 11-118312677-T-A, REVEL 0.08, MetaLR 0.05
- S55P (p.Ser55Pro), gnomAD 11-118312677-T-C, REVEL 0.08, MetaLR 0.04
- I57T (p.Ile57Thr), gnomAD 11-118312684-T-C, REVEL 0.13, MetaLR 0.14
- I57I (p.Ile57Ile), rs1948142214, gnomAD 11-118312685-A-C, CADD 3.93
- L58P (p.Leu58Pro), ExAC rs767092797, TOPMed rs767092797, gnomAD rs767092797, REVEL 0.08, MetaLR 0.07
- L58* (p.Leu58Ter), gnomAD 11-118312684-TACT, CADD 23.70
- L58L (p.Leu58Leu), gnomAD 11-118312686-C-T, CADD 0.04
- W59* (p.Trp59Ter), rs121918659, ClinGen CA150567, ClinVar RCV000087025, Ensembl rs121918659, Pathogenic
- W59R (p.Trp59Arg), ESP rs372945302, ExAC rs372945302, TOPMed rs372945302, gnomAD rs372945302, REVEL 0.68, MetaLR 0.76
- Q60Q (p.Gln60Gln), gnomAD 11-118312694-A-G, CADD 2.02
- H61Y (p.His61Tyr), rs201739383, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, Ensembl rs201739383, REVEL 0.08, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- H61R (p.His61Arg), gnomAD 11-118312696-A-G, REVEL 0.02, MetaLR 0.05
- N62I (p.Asn62Ile), ExAC rs201661177, gnomAD rs201661177, REVEL 0.21, MetaLR 0.33, Uncertain significance, Inborn genetic diseases
- N62K (p.Asn62Lys), Ensembl rs2134766628, MetaLR 0.18, MetaSVM -0.93
- D63N (p.Asp63Asn), gnomAD 11-118312701-G-A, REVEL 0.03, MetaLR 0.04
- D63D (p.Asp63Asp), gnomAD 11-118312703-T-C, CADD 0.61
- K64* (p.Lys64Ter), rs1948142385, ClinGen CA382782086, ClinVar RCV003583322, AlphaMissense 0.10, MetaLR 0.07, Pathogenic
- K64Q (p.Lys64Gln), Ensembl rs1948142385, REVEL 0.04, AlphaMissense 0.10
- K64I (p.Lys64Ile), gnomAD 11-118312705-A-T, REVEL 0.12, MetaLR 0.09
- N65T (p.Asn65Thr), gnomAD 11-118312703-TA-T, CADD 0.13
- N65D (p.Asn65Asp), gnomAD 11-118312707-A-G, REVEL 0.03, MetaLR 0.08
- N65S (p.Asn65Ser), gnomAD 11-118312708-A-G, REVEL 0.03, MetaLR 0.06
- I66V (p.Ile66Val), ExAC rs763670617, gnomAD rs763670617, REVEL 0.03, MetaLR 0.04
- I66T (p.Ile66Thr), gnomAD 11-118312711-T-C, REVEL 0.01, MetaLR 0.06
- I66M (p.Ile66Met), gnomAD 11-118312712-A-G, REVEL 0.01, MetaLR 0.06
- G67V (p.Gly67Val), Ensembl rs11551230, MetaLR 0.09, MetaSVM -1.03
- G67G (p.Gly67Gly), rs188934551, gnomAD 11-118312715-C-T, CADD 1.66
- G68D (p.Gly68Asp), Ensembl rs2134766648, MetaLR 0.05, MetaSVM -1.05
- G68S (p.Gly68Ser), rs200087808, ClinGen CA6301640, cosmic curated COSV10820, ClinVar RCV001040601, REVEL 0.08, MetaLR 0.07, Uncertain significance, Immunodeficiency 18; not provided; Inborn genetic diseases
- p.Gly68 Gly76del, rs758638097, gnomAD 11-118312698-AATG, CADD 6.48
- G68C (p.Gly68Cys), gnomAD 11-118312716-G-T, REVEL 0.09, MetaLR 0.22
- D69N (p.Asp69Asn), gnomAD 11-118312719-G-A, REVEL 0.05, MetaLR 0.09
- D69E (p.Asp69Glu), gnomAD 11-118312721-T-A, REVEL 0.07, MetaLR 0.07
- E70K (p.Glu70Lys), TOPMed rs779658490, gnomAD rs779658490, REVEL 0.03, MetaLR 0.05
- E70V (p.Glu70Val), gnomAD 11-118312723-A-T, REVEL 0.02, MetaLR 0.06
- E70E (p.Glu70Glu), gnomAD 11-118312724-G-A, CADD 0.23
- D71H (p.Asp71His), rs148647954, ClinGen CA6301641, ClinVar RCV000615505, ClinVar RCV001706451, REVEL 0.01, MetaLR 0.04, Conflicting interpretations, not provided; Immunodeficiency 18
- D71N (p.Asp71Asn), rs148647954, ClinGen CA6301643, ClinVar RCV002049849, 1000Genomes rs148647954, REVEL 0.01, MetaLR 0.04, Uncertain significance, Immunodeficiency 18
- D71Y (p.Asp71Tyr), 1000Genomes rs148647954, ESP rs148647954, ExAC rs148647954, TOPMed rs148647954, REVEL 0.04, MetaLR 0.04, Likely benign
- D72G (p.Asp72Gly), 1000Genomes rs550297587, ExAC rs550297587, gnomAD rs550297587, REVEL 0.01, MetaLR 0.04
- D72N (p.Asp72Asn), rs780235352, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62345, ExAC rs780235352, REVEL 0.00, MetaLR 0.03, Variant assessed as somatic; moderate impact.
- p.Asp72 Asp80del, rs780354214, gnomAD 11-118312716-GGTG, CADD 1.87
- D72D (p.Asp72Asp), rs2231444, gnomAD 11-118312730-T-C, CADD 0.28
- K73E (p.Lys73Glu), gnomAD rs1280473431, MetaLR 0.06, MetaSVM -1.03
- K73N (p.Lys73Asn), Ensembl rs1948142729, REVEL 0.03, MetaLR 0.06
- N74T (p.Asn74Thr), rs1948142751, ClinGen CA382782310, ClinVar RCV001334564, Ensembl rs1948142751, REVEL 0.07, MetaLR 0.11, Uncertain significance, Immunodeficiency 18
- N74K (p.Asn74Lys), gnomAD 11-118312730-T-TA, CADD 3.65
- I75V (p.Ile75Val), TOPMed rs1948142768, REVEL 0.03, MetaLR 0.02
- I75T (p.Ile75Thr), gnomAD 11-118312738-T-C, REVEL 0.10, MetaLR 0.03
- G76D (p.Gly76Asp), TOPMed rs1327454195, gnomAD rs1327454195, REVEL 0.02, MetaLR 0.08
- G76S (p.Gly76Ser), NCI-TCGA TCGA novel, MetaLR 0.07, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- G76R (p.Gly76Arg), gnomAD 11-118312740-G-C, REVEL 0.04, MetaLR 0.08
- S77G (p.Ser77Gly), ESP rs150726809
Public CD3E analysis runs
- CD3E analysis run — CD3E (370 variants) — completed 2026-08-22